Post-hoc analyses of two Phase III studies of lebrikizumab in moderate to severe asthma suggest that IL-13 inhibition is effective at preventing seasonal exacerbations in subjects with high blood eosinophil counts. Further work is required to understand and treat exacerbations that are independent of seasonal and Type 2 pathway factors.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lx5Afp
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
by Alison M. Hixon, Guixia Yu, J. Smith Leser, Shigeo Yagi, Penny Clarke, Charles Y. Chiu, Kenneth L. Tyler In 2014, the United States exp...
-
No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent...
-
by Moran Artzi, Einat Even-Sapir, Hedva Lerman Shacham, Avner Thaler, Avi Orr Urterger, Susan Bressman, Karen Marder, Talma Hendler, Nir Gil...
-
JPM, Vol. 8, Pages 5: Acknowledgement to Reviewers of Journal of Personalized Medicine in 2017 Journal of Personalized Medicine doi: 10.339...
-
Accumulating data have indicated that citrus polymethoxyflavones (PMFs) have the ability to affect brain function. In the present study, we ...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nfAPhh via IFTTT
-
Nasal nitrous oxide (nNO) is increased in allergic rhinitis (AR), but not in asthma, and is a non-invasive marker for inflammation in the na...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου